GENEVA, Oct 1 (Reuters) - Swiss pharma companies are

likely to follow Pfizer's ( PFE ) price deal with the U.S. following a

demand from President Donald Trump's administration for lower

drug prices, the head of a major Swiss chemical and

pharmaceutical industry association said on Wednesday.

Pfizer ( PFE ) and Trump said on Tuesday they had agreed a

deal in which the U.S. firm would lower prescription drug prices

in the Medicaid program to match those it charges in other

developed countries in exchange for tariff relief.

Stephan Mumenthaler, director general of Scienceindustries -

which represents around 250 Swiss chemical and pharmaceutical

companies - told Reuters he expected announcements of

"mini-deals" to come one by one in the coming days and weeks

from Swiss and global pharmaceutical companies.

"They are thinking in similar schemes...How can you omit the

margins that middlemen are taking away so that you basically

have a similar price than before, but the end consumer still

gets a lower price," he said in a video call from Basel.